ConductScience.org, home

Paper25916698

Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.

Cinar M and 8 others. Leuk Res, 2015. Cited by 26 papers, by iCite.

Cite this record

ConductScience Library. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas. Papers, record 25916698. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25916698

Download JSON
Cell line
CS-THL12 papers
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.
PubMed
Journal
Leuk Res
PubMed
Year
2015
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
26
iCite
Relative citation ratio, by iCite
0.62
iCite
Revised in PubMed
2022-03-31
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cinar MMunevver
2Rosenfelt FFred
3Rokhsar SSepehr
4Lopategui JJean
5Pillai RRaju
6Cervania MMelissa
7Pao AAndy
8Cinar BBekir
9Alkan SSerhan

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Genes, mycMajor topic
Lymphoma, B-CellMajor topic
Proto-Oncogene Proteins c-bcl-2Major topic
Bridged Bicyclo Compounds, Heterocyclic
Humans
Sulfonamides

Cited by18

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.

PMIDTitleJournalYearIn PapersSource
41681925The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System.Cancers (Basel)2026https://conductscience.org/library/papers/41681925PubMed
40569497Elevated oncogene expressions in koala infected with multiple koala retrovirus subtypes: a preliminary study.Virus Genes2025https://conductscience.org/library/papers/40569497PubMed
37924446C-Myc inhibition intensified the anti-leukemic properties of Imatinib in chronic myeloid leukemia cells.Mol Biol Rep2023https://conductscience.org/library/papers/37924446PubMed
37457123Targeting MYC-driven lymphoma: lessons learned and future directions.Cancer Drug Resist2023https://conductscience.org/library/papers/37457123PubMed
35687491Genetic characterization and drug sensitivity study of newly derived HGBL double/triple-hit lymphoma cell lines.Blood Adv2022https://conductscience.org/library/papers/35687491PubMed
35482553Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma.Hematol Oncol2022https://conductscience.org/library/papers/35482553PubMed
33777762CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements.Front Oncol2021https://conductscience.org/library/papers/33777762PubMed
32165486The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.Haematologica2021https://conductscience.org/library/papers/32165486PubMed
30523053Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with MYC and BCL2 rearrangements.Haematologica2019https://conductscience.org/library/papers/30523053PubMed
30076412Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.Oncogene2019https://conductscience.org/library/papers/30076412PubMed
29931583Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.Invest New Drugs2019https://conductscience.org/library/papers/29931583PubMed
29151814De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a case report and literature review.BMC Clin Pathol2017https://conductscience.org/library/papers/29151814PubMed
29146569Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.Cancer Discov2017https://conductscience.org/library/papers/29146569PubMed
28377453Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers.Cancer Res2017https://conductscience.org/library/papers/28377453PubMed
28074072Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.Leukemia2017https://conductscience.org/library/papers/28074072PubMed
27980306Treatment of Diffuse Large B-Cell Lymphoma.J Clin Exp Hematop2016https://conductscience.org/library/papers/27980306PubMed
27419806Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.Cell Cycle2016https://conductscience.org/library/papers/27419806PubMed
27231235Farnesiferol c induces apoptosis via regulation of L11 and c-Myc with combinational potential with anticancer drugs in non-small-cell lung cancers.Sci Rep2016https://conductscience.org/library/papers/27231235PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
BCL6604PubTator's text mininghttps://conductscience.org/library/genes/604NCBI Gene
MYC4609PubTator's text mininghttps://conductscience.org/library/genes/4609NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25916698

GET https://conductscience.org/api/papers/v1/25916698/authors